Search

Your search keyword '"Loprinzi, Charles L"' showing total 1,493 results
Start Over Author "Loprinzi, Charles L"
1,493 results on '"Loprinzi, Charles L"'

5. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial

Author

McBane, Robert D., II, Loprinzi, Charles L., Zemla, Tyler, Tafur, Alfonso, Sanfilippo, Kristen, Liu, Jane Jijun, Garcia, David A., Heun, James, Gundabolu, Krishna, Onitilo, Adedayo A., Perepu, Usha, Drescher, Monic R., Henkin, Stanislav, Houghton, Damon, Ashrani, Aneel, Billett, Henny, McCue, Shaylene A., Lee, Minji K., Le-Rademacher, Jennifer G., and Wysokinski, Waldemar E.

Published
2024
Full Text
View/download PDF

9. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors

Author

Quick, Allison M, Dockter, Travis, Le-Rademacher, Jennifer, Salani, Ritu, Hudson, Catherine, Hundley, Andrew, Terstriep, Shelby, Streicher, Lauren, Faubion, Stephanie, Loprinzi, Charles L, Coleman, Jenell S, Wang, Karen C, and Lustberg, Maryam

Subjects
Biomedical and Clinical Sciences, Health Services and Systems, Nursing, Health Sciences, Reproductive Medicine, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Prevention, Reproductive health and childbirth, Adult, Aged, Cancer Survivors, Carbon Dioxide, Female, Female Urogenital Diseases, Humans, Laser Therapy, Lasers, Gas, Menopause, Middle Aged, Pilot Projects, Single-Blind Method, Syndrome, Vagina, Cancer survivors, Dyspareunia, Genitourinary syndrome of menopause, Vaginal atrophy, Vaginal dryness, Sexual function, Atrophic vaginitis, Laser therapy, Clinical Sciences, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine, Biomedical and clinical sciences, Health sciences
Abstract

PurposeThe objectives of this study were to evaluate the feasibility and efficacy of fractional CO2 laser therapy in gynecologic cancer survivors.MethodsThis was a pilot, multi-institutional randomized sham-controlled trial of women with gynecologic cancers with dyspareunia and/or vaginal dryness. Participants were randomized to fractional CO2 laser treatment or sham laser treatment. The primary aim was to estimate the proportion of patients who had improvement in symptoms based on the Vaginal Assessment Scale (VAS). Secondary aims included changes in sexual function assessed using the Female Sexual Functioning Index (FSFI) and urinary symptoms assessed using the the Urinary Distress Inventory (UDI-6).ResultsEighteen women participated in the study, ten in the treatment arm and eight in the sham arm. The majority of participants had stage I (n = 11, 61.1 %) or II (n = 3, 16.7 %) endometrial cancer with adenocarcinoma histology (n = 9, 50 %). In total, 15 (83.3 %) of the participants completed all treatments and follow-up visit. There was no difference in the change in the median VAS score from baseline to follow-up. However, there was an improvement in change in the median total FSFI score with treatment compared with sham (Δ 6.5 vs -0.3, p = 0.02). The change in the median UDI-6 score was lower in the treatment arm (Δ -14.6 vs -2.1, p = 0.17), but this was not statistically significant. There were no reported serious adverse events.ConclusionsFractional CO2 laser therapy is feasible in gynecologic cancer survivors, with preliminary evidence of safety. In addition, there was preliminary evidence of improvement in sexual function compared with sham treatment. Clinicaltrial.gov Identifier: NCT03372720 (OSU-17261; NCI-2017-02051).

Published
2021

12. Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study.

Author

Davis, Mellar P., Ulrich, Angela, Segal, Rebecca, Gudena, Vinay, Ruddy, Kathryn J., D'Andre, Stacy, Giridhar, Karthik V., Vasireddy, Vamsi K., Agarwal, Rajiv, Azzouqa, Abdel-Ghani, Novotny, Paul, McCue, Shaylene, Bauer, Brent, and Loprinzi, Charles L.

Abstract

Simple Summary: Chemotherapy-induced neuropathy is a major clinical problem, with limited treatments available to try to reverse it. Some preliminary data suggested that palmitoylethanolamide (PEA) may effectively treat this condition. Pursuant to this, a placebo-controlled, double-blind, randomized phase 2 clinical trial was developed to look for evidence to support a future, more definitive phase 3 clinical trial. Eighty-nine patients participated in this clinical trial. Unfortunately, the data from the present phase 2 trial did not support the idea that PEA was useful in this situation. Background: Chemotherapy-induced peripheral neuropathy (CIPN) from oxaliplatin and taxane drugs is a bothersome toxicity. Palmitoylethanolamide (PEA) has been reported to improve myelinated nerve fiber function in patients experiencing painful CIPN. We conducted a double-blind, placebo-controlled, randomized trial of PEA in patients with established CIPN. Methods: Eligible patients were adults who had pain, numbness, tingling, or other symptoms of CIPN for at least three months following completion of paclitaxel, oxaliplatin, or cisplatin-based chemotherapy. Study patients were randomized to one of the two treatment groups (PEA versus placebo, both administered either once or twice daily). The CIPN20 questionnaire was assessed weekly. Results: A total of 17 males and 71 females participated in the study; most had neuropathy from paclitaxel. Most (85%) finished 8 weeks of treatment. There was no suggestion that either of the PEA arms did any better than the combined placebo arms. There was no signal of significant toxicity differences between the three study arms. Quality of life outcome measures were similar between the study arms, as were cognitive function evaluations. Discussion: PEA failed to improve established CIPN. Future trials might explore whether PEA may be effective in preventing CIPN or cognitive changes based on data that suggest it may be helpful in this situation. Conclusions: PEA failed to improve established chemotherapy-induced neuropathy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens

Author

Leal, Alexis D, Van Houten, Holly, Sangaralingham, Lindsey, Freedman, Rachel A, Jemal, Ahmedin, Neuman, Heather B, Haddad, Tufia C, Mutter, Robert W, Keegan, Theresa HM, Mougalian, Sarah S, Loprinzi, Charles L, Gross, Cary P, Shah, Nilay, and Ruddy, Kathryn J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Breast Cancer, Health Services, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cancer Survivors, Chemotherapy, Adjuvant, Cohort Studies, Cyclophosphamide, Docetaxel, Doxorubicin, Female, Humans, Insurance Claim Review, Lymph Node Excision, Mastectomy, Middle Aged, Office Visits, Paclitaxel, Breast neoplasms, Follow-up, Health care use, Outpatient, Toxicity, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundTreatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adjuvant chemotherapy regimens to better understand how differences in toxicities between regimens might affect health care use.Materials and methodsWe analyzed administrative claims data from a US commercial insurance database (OptumLabs) to identify women who received adjuvant doxorubicin/cyclophosphamide (AC), AC followed or preceded by docetaxel or paclitaxel (AC-T), AC concurrent with docetaxel or paclitaxel (TAC), or docetaxel/cyclophosphamide (TC) between 2008 and 2014. We compared mean numbers of visits per patient (adjusted for age, race/ethnicity, region, year, surgery type, radiation, chronic conditions, and previous hospitalizations) across the different regimens (TC = reference) for 12 months, starting 4 months after the end of chemotherapy.ResultsIn 6247 eligible patients, the mean adjusted number of outpatient visits per patient was significantly higher in patients who received AC-T (8.1) or TAC (7.3) than TC (6.5) or AC (6.0; P < .001 for comparisons of AC-T and TAC with TC), primarily because of differences in Medical Oncology visits. Approximately 40% did not see a primary care provider at all during this time frame.ConclusionsAC-T and TAC are associated with more subsequent outpatient visits than TC. Visits to primary care providers are infrequent during the year after completion of chemotherapy.

Published
2018

15. Hot Flashes

Author

Childs, Daniel S., Gupta, Arjun, Tofthagen, Cindy S., Loprinzi, Charles L., Kimmick, Gretchen G., editor, Shelby, Rebecca A., editor, and Sutton, Linda M., editor

Published
2021
Full Text
View/download PDF

17. Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.

Author

Stish, Brad J., primary, Mazza, Gina L., additional, Nauseef, Jones T., additional, Humeniuk, Michael Sandon, additional, Smith, Thomas J., additional, Tofthagen, Cindy, additional, Diaz Pardo, Dayssy Alexandra, additional, Chay, Christopher H., additional, Huang, Andrew Jonathan, additional, Naha, Kushal, additional, Tagawa, Scott T., additional, Chow, Selina Lai-ming, additional, Adams-Campbell, Lucile L., additional, Novotny, Paul J., additional, and Loprinzi, Charles L., additional

Published
2024
Full Text
View/download PDF

23. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group

Author

Mayo, Samantha J., Lustberg, Maryam, M. Dhillon, Haryana, Nakamura, Zev M., Allen, Deborah H., Von Ah, Diane, C. Janelsins, Michelle, Chan, Alexandre, Olson, Karin, Tan, Chia Jie, Toh, Yi Long, Oh, Jeong, Grech, Lisa, Cheung, Yin Ting, Subbiah, Ishwaria Mohan, Petranovic, Duska, D’Olimpio, James, Gobbo, Margherita, Koeppen, Susanne, Loprinzi, Charles L., Pang, Linda, Shinde, Shivani, Ntukidem, Olanipekun, and Peters, Katherine B.

Published
2021
Full Text
View/download PDF

24. Advocate-BREAST: advocates and patients' advice to enhance breast cancer care delivery, patient experience and patient centered research by 2025.

Author

O'Sullivan, Ciara C., Larson, Nicole L., Vierkant, Robert A., Smith, Mary Lou, Chauhan, Cynthia, Couch, Fergus J., Olson, Janet E., Loprinzi, Charles L., and Ruddy, Kathryn J.

Subjects
METASTATIC breast cancer, PATIENT experience, PATIENTS' attitudes, BREAST cancer, HOT flashes
Abstract

Purpose: The aims of the Advocate-BREAST project are to study and improve the breast cancer (BC) patient experience through education and patient-centered research. Methods: In December 2021, an electronic REDCap survey was circulated to 6,918 BC survivors (stage 0–4) enrolled in the Mayo Clinic Breast Disease Registry. The questionnaire asked about satisfaction with BC care delivery, and education and support receive(d) regarding BC linked concerns. Patients also ranked Quality Improvement (QI) proposals. Results: The survey received 2,437 responses. 18% had Ductal Carcinoma in Situ, 81% had early breast cancer (EBC), i.e. stage 1–3, and 2% had metastatic breast cancer (MBC). Mean age was 64 (SD 11.8), and mean time since diagnosis was 93 months (SD 70.2). 69.3% of patients received all care at Mayo Clinic. The overall experience of care was good (> 90%). The main severe symptoms recalled in year 1 were alopecia, eyebrow/eyelash thinning, hot flashes, sexual dysfunction, and cognitive issues. The main concerns recalled were fear of BC recurrence/spread; loved ones coping; fear of dying, and emotional health. Patients were most dissatisfied with information regarding sexual dysfunction, eyebrow/eyelash thinning, peripheral neuropathy, and on side effects of immunotherapy/targeted therapies. Top ranking QI projects were: i) Lifetime access to concise educational resources; ii) Holistic support programs for MBC and iii) Wellness Programs for EBC and MBC. Conclusions: Patients with early and advanced BC desire psychological support, concise educational resources, and holistic care. Implications: Focused research and QI initiatives in these areas will improve the BC patient experience. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study

Author

Salgado, Teresa M., Liu, Jin, Reed, Holly L., Quinn, Caroline S., Syverson, Jillian G., Le-Rademacher, Jennifer, Lopez, Camden L., Beutler, Andreas S., Loprinzi, Charles L., Vangipuram, Kiran, Smith, Ellen M. Lavoie, Henry, N Lynn, Farris, Karen B., and Hertz, Daniel L.

Published
2020
Full Text
View/download PDF

30. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice

Author

Huang, Kevin M., Leblanc, Alix F., Uddin, Muhammad Erfan, Kim, Ji Young, Chen, Mingqing, Eisenmann, Eric D., Gibson, Alice A., Li, Yang, Hong, Kristen W., DiGiacomo, Duncan, Xia, Sherry H., Alberti, Paola, Chiorazzi, Alessia, Housley, Stephen N., Cope, Timothy C., Sprowl, Jason A., Wang, Jing, Loprinzi, Charles L., Noonan, Anne, Lustberg, Maryam B., Cavaletti, Guido, Pabla, Navjot, Hu, Shuiying, and Sparreboom, Alex

Subjects
Genetic engineering, Genetically modified organisms, Colorectal cancer, Duloxetine, Proteins, Dasatinib, Neurons, Health care industry, The Ohio State University
Abstract

Peripheral neurotoxicity is a debilitating condition that afflicts up to 90% of patients with colorectal cancer receiving oxaliplatin-containing therapy. Although emerging evidence has highlighted the importance of various solute carriers to the toxicity of anticancer drugs, the contribution of these proteins to oxaliplatin-induced peripheral neurotoxicity remains controversial. Among candidate transporters investigated in genetically engineered mouse models, we provide evidence for a critical role of the organic cation transporter 2 (OCT2) in satellite glial cells in oxaliplatin-induced neurotoxicity, and demonstrate that targeting OCT2 using genetic and pharmacological approaches ameliorates acute and chronic forms of neurotoxicity. The relevance of this transport system was verified in transporter-deficient rats as a secondary model organism, and translational significance of preventive strategies was demonstrated in preclinical models of colorectal cancer. These studies suggest that pharmacological targeting of OCT2 could be exploited to afford neuroprotection in cancer patients requiring treatment with oxaliplatin., Introduction Clinical use of the chemotherapeutic agent oxaliplatin is associated with a characteristic pattern of peripheral neurotoxicity that affects more than 90% of patients (1). The onset of neurotoxicity may [...]

Published
2020
Full Text
View/download PDF

31. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102

Author

Cathcart-Rake, Elizabeth, Novotny, Paul, Leon-Ferre, Roberto, Le-Rademacher, Jennifer, Storrick, Elizabeth M., Adjei, Araba A., Terstriep, Shelby, Glaser, Rebecca, Giuliano, Armando, Mitchell, William R., Page, Seth, Austin, Colleen, Deming, Richard L., Ferreira, Margaret A., Lafky, Jacqueline M., Birrell, Stephen N., and Loprinzi, Charles L.

Published
2021
Full Text
View/download PDF

34. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors

Author

Quick, Allison M., Zvinovski, Filadelfiya, Hudson, Catherine, Hundley, Andrew, Evans, Cynthia, Suresh, Anupama, Stephens, Julie A., Arthur, Elizabeth, Ramaswamy, Bhuvaneswari, Reinbolt, Raquel E., Noonan, Anne M., VanDeusen, Jeffrey Bryan, Wesolowski, Robert, Stover, Daniel G., Williams, Nicole Olivia, Sardesai, Sagar D., Smith, Karen L., Faubion, Stephanie S., Loprinzi, Charles L., and Lustberg, Maryam B.

Published
2020
Full Text
View/download PDF

44. Changes in amount and intensity of physical activity over time in breast cancer survivors

Author

Marell, Paulina S, primary, Vierkant, Robert A, additional, Olson, Janet E, additional, Herrmann, Joerg, additional, Larson, Nicole L, additional, Lebrasseur, Nathan K, additional, D’Andre, Stacy D, additional, Ehlers, Diane K, additional, Stan, Daniela L, additional, Cheville, Andrea L, additional, Barksdale, Toure, additional, Loprinzi, Charles L, additional, Couch, Fergus J, additional, and Ruddy, Kathryn J, additional

Published
2023
Full Text
View/download PDF

46. Contributors

Author

Abbruzzese, James L., primary, Abdel-Wahab, Omar, additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffrey S., additional, Abramson, Jeremy S., additional, Aisner, Dara L., additional, Alonso-Basanta, Michelle, additional, Anampa, Jesus, additional, Anderson, Megan E., additional, Antonarakis, Emmanuel S., additional, Aplenc, Richard, additional, Appelbaum, Frederick R., additional, Araujo, Luiz H., additional, Asban, Ammar, additional, Ashwood, Edward, additional, Awan, Farrukh T., additional, Aylward, Juliet L., additional, Balar, Arjun V., additional, Balentine, Courtney J., additional, Barta, Stefan K., additional, Bartlett, Nancy, additional, Basen-Engquist, Karen, additional, Beaupin, Lynda Kwon, additional, Berkowitz, Ross S., additional, Berry, Donald A., additional, Bevers, Therese, additional, Boggess, John F., additional, Brahmer, Julie R., additional, Brown, Janet, additional, Brown, Karen, additional, Brown, Powel, additional, Browner, Ilene, additional, Bunn, Paul A., additional, Burns, William R., additional, Byrd, John C., additional, Cadoo, Karen, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Castillo, Jorge J., additional, Chang, Alfred E., additional, Chang, Eric, additional, Chanock, Stephen J., additional, Chapuy, Claudia I., additional, Chauhan, Vikash P., additional, Chen, Herbert, additional, Chen, Ronald C., additional, Cheung, Nai-Kong V., additional, Choe, Jennifer H., additional, Christian, Michaele C., additional, Cinciripini, Paul M., additional, Clarke, Michael F., additional, Coleman, Robert E., additional, Coleman, Robert L., additional, Coletta, Adriana M., additional, Collins, Jerry M., additional, Connors, Jean M., additional, Cools, Michael, additional, Coombes, Kevin R., additional, Cortes, Jorge, additional, Costa, Mauro W., additional, Covey, Anne, additional, Cowan, Kenneth H., additional, Crane, Christopher H., additional, Crawford, Jeffrey, additional, Crooks, Kristy, additional, Culkin, Daniel J., additional, Czito, Brian G., additional, Dalerba, Piero, additional, Dalmau, Josep, additional, Dang, Mai, additional, D'Angelica, Michael, additional, Davies, Kurtis D., additional, Davis, Myrtle, additional, Dea, Nicolas, additional, De Jesus-Acosta, Ana, additional, DeMarzo, Angelo M., additional, DeWeese, Theodore L., additional, Diehn, Maximilian, additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Do, Khanh T., additional, Dobrenkov, Konstantin, additional, Dome, Jeffrey S., additional, Doroshow, James H., additional, Dorsey, Jay F., additional, Dubard-Gault, Marianne, additional, DuBois, Steven G., additional, Duda, Dan G., additional, Dunlop, Malcolm, additional, Duska, Linda R., additional, Duvic, Madeleine, additional, El Dika, Imane, additional, El-Serag, Hashem, additional, Engelmann, Jeffrey M., additional, Ettinger, David S., additional, Fashoyin-Aje, Lola A., additional, Fearon, Eric R., additional, Ford, James M., additional, Franklin, Wilbur A., additional, Freer, Phoebe E., additional, Freidlin, Boris, additional, Freifeld, Alison G., additional, Friedlander, Terence W., additional, Friedman, Debra L., additional, Fuller, Arian F., additional, Galluzzi, Lorenzo, additional, Gebhardt, Mark C., additional, George, Daniel J., additional, Geyer, Mark B., additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Goldner, Whitney, additional, Goldstein, Donald P., additional, Goodman, Annekathryn, additional, Goodman, Karyn A., additional, Gordon, Kathleen, additional, Graeff-Armas, Laura, additional, Greenstein, Alexander J., additional, Grossman, Stuart A., additional, Grupp, Stephan, additional, Gupta, Arjun, additional, Haider, Irfanullah, additional, Haigentz, Missak, additional, Hainsworth, John D., additional, Haithcock, Benjamin E., additional, Hallemeier, Christopher L., additional, Hanash, Samir, additional, Hanrahan, Aphrothiti J., additional, Harding, James, additional, Harrison, Michael R., additional, Hasham, Muneer G., additional, Hawk, Ernest, additional, Hayman, Jonathan, additional, Heinlen, Jonathan E., additional, Henry, N. Lynn, additional, Herman, Joseph, additional, Hobbs, Brian P., additional, Holen, Ingunn, additional, Horn, Leora, additional, Horowitz, Neil S., additional, Horwitz, Steven M., additional, Houghton, Odette, additional, Howard, Scott C., additional, Hudis, Clifford A., additional, Hunger, Stephen P., additional, Hurria, Arti, additional, Ilson, David H., additional, Im, Annie, additional, Iyer, Gopa, additional, Jaffee, Elizabeth M., additional, Jagsi, Reshma, additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jatoi, Aminah, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Johnston, Brian, additional, Johnston, Patrick G., additional, Judy, Kevin D., additional, Kachnic, Lisa A., additional, Kaidar-Person, Orit, additional, Kalva, Sanjeeva, additional, Kamin, Deborah Y., additional, Kantarjian, Hagop, additional, Karakousis, Giorgos, additional, Karam-Hage, Maher, additional, Kaskas, Nadine M., additional, Kastan, Michael B., additional, Katabi, Nora, additional, Kaul, Daniel R., additional, Kelley, Scott R., additional, Kemeny, Nancy, additional, Kent, Erin E., additional, Kepp, Oliver, additional, Khagi, Simon, additional, Kilgore, Joshua E., additional, Kim, D. Nathan, additional, Kleinschmidt-DeMasters, Bette K., additional, Korn, Edward L., additional, Kroemer, Guido, additional, Ku, Geoffrey Y., additional, Kummar, Shivaani, additional, Ky, Bonnie, additional, Laheru, Daniel A., additional, Lambert, Paul F., additional, Lawler, Mark, additional, Le-Rademacher, Jennifer G., additional, Lee, John Y.K., additional, Lee, Nancy Y., additional, Lee, Susanna L., additional, Leeman, Jonathan E., additional, Linkermann, Andreas, additional, Liu, Jinsong, additional, Lo, Simon, additional, Locasale, Jason W., additional, Loprinzi, Charles L., additional, Lowery, Maeve, additional, Ludwig, Emmy, additional, Lunning, Matthew A., additional, Lustig, Robert A., additional, Machtay, Mitchell, additional, Mackall, Crystal, additional, Mahvi, David A., additional, Mahvi, David M., additional, Maity, Amit, additional, Majithia, Neil, additional, Malumbres, Marcos, additional, Maresso, Karen Colbert, additional, Martin, John D., additional, Matsuo, Koji, additional, Matthews, Natalie H., additional, Mauro, Lauren, additional, Mayer, R. Samuel, additional, McCaskill-Stevens, Worta, additional, McNamara, Megan A., additional, Mehta-Shah, Neha, additional, Merritt, Robert E., additional, Milowsky, Matthew I., additional, Minasian, Lori M., additional, Mitchell, Tara C., additional, Mitsis, Demytra, additional, Mollica, Michelle, additional, Mooney, Margaret, additional, Moustafa, Farah, additional, Nabati, Lida, additional, Naidoo, Jarushka, additional, Narang, Amol, additional, Nelson, Heidi, additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niglas, Mark, additional, O'Connor, Tracey, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O’Reilly, Eileen M., additional, Ostrander, Elaine A., additional, Pappas-Taffer, Lisa, additional, Pardoll, Drew, additional, Park, Jae H., additional, Patel, Anery, additional, Patel, Anish J., additional, Patierno, Steven R., additional, Pavletic, Steven Z., additional, Phillips, Peter C., additional, Post, Miriam D., additional, Pruitt, Amy A., additional, Querfeld, Christiane, additional, Rabius, Vance A., additional, Rajkumar, S. Vincent, additional, Ramadan, Mohammad O., additional, Rankin, Erinn B., additional, Reddy, Sushanth, additional, Reid, Michael A., additional, Reznik, Scott, additional, Rizack, Tina, additional, Robinson, Jason D., additional, Robinson-Bostom, Leslie, additional, Rodriguez-Galindo, Carlos, additional, Romesser, Paul B., additional, Rosen, Steven T., additional, Rosenfeld, Myrna R., additional, Rosenthal, Nadia, additional, Ross, Meredith, additional, Rowland, Julia H., additional, Russell, Anthony H., additional, Sabel, Michael S., additional, Sahgal, Arjun, additional, Salinas, Ryan D., additional, Salo-Mullen, Erin E., additional, Salto-Tellez, Manuel, additional, Sanderson, Sydney M., additional, Sandlund, John T., additional, Santana, Victor M., additional, Savage, Michelle, additional, Schreiber, Eric C., additional, Schuchter, Lynn, additional, Schultz, Liora, additional, Seiden, Michael V., additional, Sellers, Morgan M., additional, Shah, Payal D., additional, Shia, Jinru, additional, Shilo, Konstantin, additional, Small, Eric, additional, Smith, Angela B., additional, Snow, Stephen N., additional, Solit, David B., additional, Sood, Anil K., additional, Soto-Perez-de-Celis, Enrique, additional, Sparano, Joseph A., additional, Spiegelman, Vladimir S., additional, Spunt, Sheri L., additional, Stadler, Zsofia K., additional, Steensma, David P., additional, Stone, Richard M., additional, Stranne, Steven Kent, additional, Stratton, Kelly, additional, Sugden, Bill, additional, Swanson, Andrew M., additional, Tallman, Martin S., additional, Talmadge, James E., additional, Teachey, David T., additional, Teba, Catalina V., additional, Tefferi, Ayalew, additional, Teh, Bin Tean, additional, Teng, Joyce M.C., additional, Tepper, Joel E., additional, Thaker, Premal H., additional, Thrift, Aaron P., additional, Tran, Arthur-Quan, additional, Triska, Grace, additional, Trump, Donald, additional, Tsai, Kenneth, additional, Tseng, Chia-Lin, additional, Tseng, Diane, additional, Van Schaeybroeck, Sandra, additional, Van Tine, Brian A., additional, Vanness, Erin R., additional, Varadhachary, Gauri, additional, Varella-Garcia, Marileila, additional, Wahl, Richard L., additional, Walsh, Michael F., additional, Wang, Thomas, additional, Weiss, Jared, additional, Weissman, Irving L., additional, Westin, Shannon N., additional, White, Jeffrey D., additional, Wilson, Richard, additional, Wong, Richard J., additional, Wood, Gary S., additional, Xu, Yaohui G., additional, Xu-Welliver, Meng, additional, Yust-Katz, Shlomit, additional, Zagar, Timothy, additional, Zeman, Elaine M., additional, Zhang, Tian, additional, and Zwiebel, James A., additional

Published
2020
Full Text
View/download PDF

47. Oral Complications

Author

Majithia, Neil, primary, Hallemeier, Christopher L., additional, and Loprinzi, Charles L., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results